skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Lutetium Lu-177 Girentuximab (Code C66978)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lutetium Lu-177 Girentuximab

Definition: A radioimmunoconjugate consisting of the chimeric monoclonal antibody cG250 linked to the low energy beta-emitting radioisotope Lutetium 177, via the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), with potential antineoplastic activity. The antibody moiety of lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250 binds to renal cell carcinoma (RCC) cells expressing the RCC-associated antigen G250; a cytotoxic dose of beta radiation is selectively delivered to G250-expressing RCC cells upon internalization of the radioimmunoconjugate.

Label: Lutetium Lu-177 Girentuximab

NCI Thesaurus Code: C66978 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1881485  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Lutetium Lu-177 Girentuximab
Lutetium Lu-177-DOTA-Chimeric Monoclonal Antibody cG250
Lutetium-177 Labeled cG250

External Source Codes: 
PDQ Closed Trial Search ID 531051
PDQ Open Trial Search ID 531051 (check for NCI PDQ open clinical trial info)
UMLS CUI C1881485

Other Properties:
     Name Value (qualifiers indented underneath)
code C66978
Legacy_Concept_Name Lutetium_Lu_177-DOTA-Chimeric_Monoclonal_Antibody_cG250
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom